Literature DB >> 19538134

The role of OX40-mediated co-stimulation in T-cell activation and survival.

William L Redmond1, Carl E Ruby, Andrew D Weinberg.   

Abstract

The extent of T-cell activation, proliferation, and survival that follows T-cell receptor (TCR) ligation is controlled by several factors, including the strength of TCR stimulation, the availability of prosurvival cytokines, and the presence or absence of co-stimulatory signals. In addition to engagement of the CD28 co-stimulatory receptor by its natural ligands, B7.1 (CD80) and B7.2 (CD86), recent work has begun to elucidate the mechanisms by which signaling through the OX40 (CD134) co-stimulatory receptor, a member of the tumor necrosis factor receptor (TNFR) superfamily, affects T-cell responses. Importantly, OX40 ligation has been shown to augment CD4 and CD8 T-cell clonal expansion, effector differentiation, survival, and in some cases, abrogate the suppressive activity of regulatory FoxP3+CD25+CD4+ T cells. In this review, we focus on the mechanisms regulating OX40 expression on activated T cells as well as the role of OX40-mediated co-stimulation in boosting T-cell clonal expansion, effector differentiation, and survival.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19538134      PMCID: PMC3180959          DOI: 10.1615/critrevimmunol.v29.i3.10

Source DB:  PubMed          Journal:  Crit Rev Immunol        ISSN: 1040-8401            Impact factor:   2.214


  102 in total

Review 1.  Cross-presentation, dendritic cells, tolerance and immunity.

Authors:  W R Heath; F R Carbone
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

Review 2.  Signaling domains of the interleukin 2 receptor.

Authors:  S L Gaffen
Journal:  Cytokine       Date:  2001-04-21       Impact factor: 3.861

3.  Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses.

Authors:  I Gramaglia; A D Weinberg; M Lemon; M Croft
Journal:  J Immunol       Date:  1998-12-15       Impact factor: 5.422

Review 4.  Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation.

Authors:  B Salomon; J A Bluestone
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

5.  Amelioration of experimental autoimmune encephalomyelitis with anti-OX40 ligand monoclonal antibody: a critical role for OX40 ligand in migration, but not development, of pathogenic T cells.

Authors:  C Nohara; H Akiba; A Nakajima; A Inoue; C S Koh; H Ohshima; H Yagita; Y Mizuno; K Okumura
Journal:  J Immunol       Date:  2001-02-01       Impact factor: 5.422

6.  The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion.

Authors:  I Gramaglia; A Jember; S D Pippig; A D Weinberg; N Killeen; M Croft
Journal:  J Immunol       Date:  2000-09-15       Impact factor: 5.422

7.  Contribution of OX40/OX40 ligand interaction to the pathogenesis of rheumatoid arthritis.

Authors:  T Yoshioka; A Nakajima; H Akiba; T Ishiwata; G Asano; S Yoshino; H Yagita; K Okumura
Journal:  Eur J Immunol       Date:  2000-10       Impact factor: 5.532

8.  Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth.

Authors:  J Kjaergaard; J Tanaka; J A Kim; K Rothchild; A Weinberg; S Shu
Journal:  Cancer Res       Date:  2000-10-01       Impact factor: 12.701

Review 9.  OX-40: life beyond the effector T cell stage.

Authors:  A D Weinberg; A T Vella; M Croft
Journal:  Semin Immunol       Date:  1998-12       Impact factor: 11.130

10.  Development of allergic inflammation in a murine model of asthma is dependent on the costimulatory receptor OX40.

Authors:  A G Jember; R Zuberi; F T Liu; M Croft
Journal:  J Exp Med       Date:  2001-02-05       Impact factor: 14.307

View more
  84 in total

Review 1.  Signaling through OX40 enhances antitumor immunity.

Authors:  Shawn M Jensen; Levi D Maston; Michael J Gough; Carl E Ruby; William L Redmond; Marka Crittenden; Yuhuan Li; Sachin Puri; Christian H Poehlein; Nick Morris; Magdalena Kovacsovics-Bankowski; Tarsem Moudgil; Chris Twitty; Edwin B Walker; Hong-Ming Hu; Walter J Urba; Andrew D Weinberg; Brendan Curti; Bernard A Fox
Journal:  Semin Oncol       Date:  2010-10       Impact factor: 4.929

2.  Antiapoptotic Clone 11-Derived Peptides Induce In Vitro Death of CD4+ T Cells Susceptible to HIV-1 Infection.

Authors:  Anastassia Mikhailova; José Carlos Valle-Casuso; Annie David; Valérie Monceaux; Stevenn Volant; Caroline Passaes; Amal Elfidha; Michaela Müller-Trutwin; Jean-Luc Poyet; Asier Sáez-Cirión
Journal:  J Virol       Date:  2020-07-01       Impact factor: 5.103

3.  Age-dependent divergent effects of OX40L treatment on the development of diabetes in NOD mice.

Authors:  Christine S Haddad; Palash Bhattacharya; Khaled Alharshawi; Alejandra Marinelarena; Prabhakaran Kumar; Osama El-Sayed; Hatem A Elshabrawy; Alan L Epstein; Bellur S Prabhakar
Journal:  Autoimmunity       Date:  2016-05-31       Impact factor: 2.815

4.  Activation of OX40 prolongs and exacerbates autoimmune experimental uveitis.

Authors:  Xiumei Wu; James T Rosenbaum; Grazyna Adamus; Gary L Zhang; Jie Duan; Andrew Weinberg; Zili Zhang
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-10-31       Impact factor: 4.799

5.  Antibodies targeting human OX40 expand effector T cells and block inducible and natural regulatory T cell function.

Authors:  Kui S Voo; Laura Bover; Megan L Harline; Long T Vien; Valeria Facchinetti; Kazuhiko Arima; Larry W Kwak; Yong J Liu
Journal:  J Immunol       Date:  2013-09-06       Impact factor: 5.422

6.  Small-molecule modulators of the OX40-OX40 ligand co-stimulatory protein-protein interaction.

Authors:  Yun Song; Emilio Margolles-Clark; Allison Bayer; Peter Buchwald
Journal:  Br J Pharmacol       Date:  2014-11       Impact factor: 8.739

7.  Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity.

Authors:  William L Redmond; Stefanie N Linch; Melissa J Kasiewicz
Journal:  Cancer Immunol Res       Date:  2013-11-11       Impact factor: 11.151

8.  Anaphylaxis caused by repetitive doses of a GITR agonist monoclonal antibody in mice.

Authors:  Judith T Murphy; Andre P Burey; Amy M Beebe; Danling Gu; Leonard G Presta; Taha Merghoub; Jedd D Wolchok
Journal:  Blood       Date:  2014-02-20       Impact factor: 22.113

Review 9.  Chimeric antigen receptor-engineered T cells for immunotherapy of cancer.

Authors:  Marc Cartellieri; Michael Bachmann; Anja Feldmann; Claudia Bippes; Slava Stamova; Rebekka Wehner; Achim Temme; Marc Schmitz
Journal:  J Biomed Biotechnol       Date:  2010-05-05

Review 10.  Molecular mechanisms of T cell co-stimulation and co-inhibition.

Authors:  Lieping Chen; Dallas B Flies
Journal:  Nat Rev Immunol       Date:  2013-03-08       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.